Clinical Trial Update: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) [Phase 3]

View source ↗

Summary

Tanabe's MT-2412 was studied as an add-on to canagliflozin in Japanese adults with type 2 diabetes in a Phase 3 confirmatory trial; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)
• MT-2412

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-08-16